Newsroom | 95176 results

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending December 31 of each year. There was an eight-month transition period from May 1, 2025 to December 31, 2025 and these results are presented within the condensed consolidated finan...

RAHWAY, N.J., & FOSTER CITY, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. This equates to approximately $5.7 billion net of acquired cash a...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune disorders, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 7,050 shares of the Company’s common stock at an exercise price per share of $21.41, which was th...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved a label update for ADSTILADRIN® (nadofaragene firadenovec-vncg), enabling an accelerated water-bath thawing method, completed in about 25 minutes, to enhance efficient clinical preparation for healthcare teams. ADSTILADRIN is the first and only FDA-approved non-replicating intravesical gene-therapy for the treatment of adult patients with high-risk Bacillus Ca...

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you jo...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under th...

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Governor Ron DeSantis has signed into law emergency legislation restoring access to life-saving HIV medications for more than 12,000 Floridians who lost coverage when the Florida Department of Health cut the state’s AIDS Drug Assistance Program on March 1. The legislation, which passed both chambers of the Florida Legislature unanimously, appropriates $30.9 million in emergency bridge funding through June 30, 2026, restores Florida’s AIDS Drug Assistance...

英國諾丁漢，法國梅蘭--(BUSINESS WIRE)--(美國商業資訊)-- 互動式應答技術（IRT）領域值得信賴的領導企業Perceptive eClinical與全球領先的電子臨床結果評估（eCOA）解決方案供應商Kayentis今日宣布建立策略合作夥伴關係，共同為臨床試驗提供全面整合的一流eCOA-IRT解決方案。此次合作將兩個專業平台無縫融合，為試驗發起方和受託研究機構（CRO）提供超越單一供應商系統的強大替代方案。 此次合作直接回應了產業面臨的最緊迫挑戰之一：分散數位生態系統帶來的營運負擔。隨著試驗日益複雜，試驗中心和研究團隊越來越依賴多個不相連的工具，從而導致了資料重複輸入、工作流程重複以及不必要的核對步驟。Perceptive eClinical與Kayentis共同推出的解決方案透過將IRT和eCOA兩大核心系統整合到一個精簡且可互通的工作流程中，有效緩解了這些痛點，從而提升了效率、資料品質和整體使用者體驗。 「我們與Kayentis的合作體現了我們共同的願景，即建立一個更加統一與智慧化的臨床技術環境。」Perceptive eClinical執行長Mario Pap...

PECHINO--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), un’azienda biotecnologica globale che dà impulso alla ricerca e sviluppo di farmaci innovativi basati su anticorpi impiegando tecnologie all’avanguardia, oggi ha annunciato una collaborazione strategica con Moonlight Bio, Inc., società biotecnologica con sede a Seattle, pioniera nelle terapie cellulari all’avanguardia. Questa collaborazione mira a sviluppare terapie cellulari all’ava...

LIESTAL, Svizzera--(BUSINESS WIRE)--Curatis Holding AG (SIX:CURN, “Curatis”) annuncia ricavi aziendali pari a 10,8 milioni di franchi (+57%) per il 2025. Curatis AG ha riportato un aumento organico del fatturato nella sua attività di distribuzione pari al 13%, da 9,5 milioni di franchi a 10,8 milioni di franchi. Il risultato netto è migliorato da una perdita di 4,3 milioni di franchi nel 2024 a una perdita di 1,4 milioni di franchi nel 2025. Ulteriori importanti dichiarazioni Nel settembre 2025...